BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther 2020;210:107518. [PMID: 32109490 DOI: 10.1016/j.pharmthera.2020.107518] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu S, Hui Z, Duan J, Garrido C, Xie T, Ye XY. Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present. Expert Opin Ther Pat 2022. [PMID: 35001778 DOI: 10.1080/13543776.2022.2027911] [Reference Citation Analysis]
2 Marx C, Schaarschmidt MU, Kirkpatrick J, Marx-Blümel L, Halilovic M, Westermann M, Hoelzer D, Meyer FB, Geng Y, Buder K, Schadwinkel HM, Siniuk K, Becker S, Thierbach R, Beck JF, Sonnemann J, Wang ZQ. Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing's sarcoma cells. Cell Biosci 2021;11:57. [PMID: 33743824 DOI: 10.1186/s13578-021-00571-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, Cai X. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13:118. [PMID: 32883316 DOI: 10.1186/s13045-020-00956-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
4 Barnieh FM, Loadman PM, Falconer RA. Progress towards a clinically-successful ATR inhibitor for cancer therapy. Current Research in Pharmacology and Drug Discovery 2021;2:100017. [DOI: 10.1016/j.crphar.2021.100017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Raimundo L, Calheiros J, Saraiva L. Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. Cancers (Basel) 2021;13:3438. [PMID: 34298653 DOI: 10.3390/cancers13143438] [Reference Citation Analysis]
6 Alemi F, Malakoti F, Vaghari-Tabari M, Soleimanpour J, Shabestani N, Sadigh AR, Khelghati N, Asemi Z, Ahmadi Y, Yousefi B. DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma. J Cell Physiol 2022. [PMID: 35383920 DOI: 10.1002/jcp.30721] [Reference Citation Analysis]
7 Gao A, Guo M. Epigenetic based synthetic lethal strategies in human cancers. Biomark Res 2020;8:44. [PMID: 32974031 DOI: 10.1186/s40364-020-00224-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Shang XY, Yu XQ, Yao GD, Song SJ. Daphnegiravone D from Daphne giraldii induces cell death by targeting ATR in Hep3B cells. Bioorg Chem 2021;110:104802. [PMID: 33730672 DOI: 10.1016/j.bioorg.2021.104802] [Reference Citation Analysis]
9 McMahon JT, Faraj RR, Adamson DC. Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. Expert Opin Investig Drugs 2020;29:1389-406. [PMID: 33040640 DOI: 10.1080/13543784.2020.1836154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wengner AM, Scholz A, Haendler B. Targeting DNA Damage Response in Prostate and Breast Cancer. Int J Mol Sci 2020;21:E8273. [PMID: 33158305 DOI: 10.3390/ijms21218273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
11 Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. European Journal of Medicinal Chemistry 2022;230:114109. [DOI: 10.1016/j.ejmech.2022.114109] [Reference Citation Analysis]
12 Bin H, Chen P, Wu M, Wang F, Lin G, Pan S, Liu J, Mu B, Nan J, Huang Q, Li L, Yang S. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114187] [Reference Citation Analysis]
13 Gorecki L, Andrs M, Korabecny J. Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers (Basel) 2021;13:795. [PMID: 33672884 DOI: 10.3390/cancers13040795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Arend RC, Jackson-Fisher A, Jacobs IA, Chou J, Monk BJ. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. Cancer Biol Ther 2021;22:89-105. [PMID: 33427569 DOI: 10.1080/15384047.2020.1868937] [Reference Citation Analysis]
15 Huang W, Tang H, Wen F, Lu X, Li Q, Shu P. Jianpi-yangwei decoction inhibits DNA damage repair in the drug resistance of gastric cancer by reducing FEN1 expression. BMC Complement Med Ther 2020;20:196. [PMID: 32586310 DOI: 10.1186/s12906-020-02983-8] [Reference Citation Analysis]
16 Scarborough JA, Scott JG. Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. Semin Radiat Oncol 2022;32:42-53. [PMID: 34861995 DOI: 10.1016/j.semradonc.2021.09.001] [Reference Citation Analysis]
17 Sadoughi F, Mirsafaei L, Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, Montazer M, Hosseinpour M, Yousefi B. The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem? DNA Repair (Amst) 2021;101:103074. [PMID: 33640757 DOI: 10.1016/j.dnarep.2021.103074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Li X, Dean DC, Cote GM, Zou L, Hornicek FJ, Yu S, Duan Z. Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma. Ther Adv Med Oncol 2020;12:1758835920956900. [PMID: 32973933 DOI: 10.1177/1758835920956900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Wang M, Chen S, Ao D. Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm (2020) 2021;2:654-91. [PMID: 34977872 DOI: 10.1002/mco2.103] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Schleicher EM, Moldovan GL. CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery. FEBS J 2021. [PMID: 34601817 DOI: 10.1111/febs.16217] [Reference Citation Analysis]